DR319 / Huadong Medicine, Zhejiang Doer Biologics - LARVOL DELTA

DR319-DP: A Nectin-4/Trop-2 bispecific ADC with an avidity-driven VHH design and dual-MOA payloads (AACR 2026) - "In clinical attempts, the combination of sacituzumab govitecan (SG) and enfortumab vedotin (EV) has demonstrated substantially improved efficacy in early-phase trials for metastatic urothelial carcinoma. The incorporation of synergistic dual-MOA payloads (DP) into DR319 provides a comprehensive strategy to maximize efficacy and overcome resistance. These preclinical data strongly support the clinical development of DR319 ADCs as a potential best-in-class therapeutic for solid tumors."

ADC • Bispecific • Oncology • Solid Tumor • Urothelial Cancer • NECTIN4